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ABSTRACT
Mitral regurgitation (MR) is one of the most common valvular heart diseases. According to the current 
guidelines, surgical treatment may be considered in symptomatic patients with severe functional MR. 
A therapy using the MitralClip (MC) system may be an alternative approach for patients who are at high 
surgical risk. The presented case report illustrates, as the first one in Poland, a very rare need for the 
implantation of 4 MC devices in a symptomatic patient with severe functional MR and indicates feasibility 
and safety of such management. 
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Introduction
Mitral regurgitation (MR) is one of the most com-
mon valvular diseases. Functional or ischemic MR, 
which results from enlargement and remodeling of the 
left ventricle (LV), is especially common in patients with 
chronic heart failure (CHF). According to the current 
guidelines, surgical treatment may be considered in 
patients with severe functional MR who remain symp-
tomatic despite optimal medical treatment, with left 
ventricular ejection fraction (LVEF) higher than 30% 
and low comorbidity (IIb/C) [1]. A therapy using the 
MitraClip (MC) system may be an alternative approach 
for patients who are at high surgical risk [2–5]. The MC 
is a catheter-based system which allows reduction of 
MR by creating a double-orifice valve after edge-to-
edge clipping of mitral valve leaflets. The aim of the 
present paper is to describe the first MC procedure of 
4 clips implantation in one patient performed in Poland. 
Case report
A 74-year-old man was admitted to the Department 
of Cardiology, University Hospital No. 1 in Bydgoszcz 
at the beginning of December 2015 for the MC proce-
dure. The patient had a history of inferior and lateral 
wall myocardial infarction (MI) in 1995 and coronary 
artery bypass surgery (CABG) in 1996. Until January 
2015 he was treated several times with percutaneous 
coronary intervention (PCI) and stent implantation. 
Due to complete atrioventricular block, he had a dual 
chamber peacemaker (DDD) implanted in 2002, 
which was upgraded to cardiac resynchronization in 
2011. Moreover, the patient had a history of arterial 
hypertension, chronic kidney disease, gout, nodular 
goiter, benign prostatic hyperplasia, obesity (body 
mass index of 31.02 kg/m2) and underwent laparo-
scopic cholecystectomy. Last year the patient was 
hospitalized a few times because of exacerbation of 
CHF and symptomatic severe MR. In March 2015 he 
had dialysis due to acute renal failure. After PCI in 
January 2015 the patient was on double antiplatelet 
therapy and was also treated with proton pump inhib-
itor, statin, beta-blocker, diuretics, angiotensin-con-
verting-enzyme inhibitors, amiodarone, potassium 
chloride, alpha1 adrenergic receptor antagonist, and 
levothyroxine. Despite appropriate medical therapy, 
he stayed in NYHA (New York Heart Association) 
class III/IV. Transthoracic echocardiography (TTE) 
performed two months earlier showed dilatation of the 
left atrium (LA = 58 mm), and dilatation of the right and 
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left ventricle (LV = 57/65 mm; RV = 32 mm). MR was 
severe (4+), likely due to the dilatation of LV. Vena con-
tracta, mitral valve leaflets coaptation depth and length 
were 8 mm, 7 mm and 4 mm, respectively. Length of 
the anterior leaflet was 25 mm and posterior 15 mm. 
Echocardiography also revealed small/medium tricus-
pid regurgitation and elevated to 46 mm Hg pulmonary 
artery systolic pressure. Myocardial contractility was 
impaired, with LVEF 35% due to akinesia of the basal 
and medial segments of the lateral wall, akinesia of 
the apical and medial segments of the inferior wall 
and hypokinesis of the interventricular septum and 
basal segment of the inferior wall. Transesophageal 
echocardiography (TEE) performed on the same day 
confirmed the severity of MR with vena contracta 
8 mm (Fig. 1), mitral valve leaflets coaptation depth 
and length of 9 mm, 10 mm and 4mm respectively. 
The length of the anterior leaflet was 30 mm and the 
posterior 17 mm. There was at least double-flowed jet 
of regurgitation in the intercommissural view, with vena 
contracta 8 mm for each jet. In the left atrial append-
age, an inhomogeneous echo (10 × 4 mm) was seen. 
Coronary angiography showed multivessel disease 
with borderline left main distal stenosis, occlusions of 
the mid left anterior descending artery (LAD), proximal 
circumflex (Cx) artery and proximal right coronary ar-
tery (RCA). There were also: a patent arterial graft (the 
left internal mammary artery to the LAD), an occluded 
saphenous venous graft (SVG) to the RCA and a pat-
ent SVG to the obtuse margin and distal Cx. After the 
Heart Team discussion, the patient was disqualified 
from the surgery, due to the poor clinical condition 
and high surgical risk (EuroSCORE II = 10.69%), and 
a decision to perform the MitraClip procedure was 
made. The procedure was performed under general 
anesthesia, with the angiographic and TEE guidance. 
After the right femoral vein puncture, the transatrial 
puncture was performed in the precise, prespecified 
location. The MitraClip system was then introduced 
to the left atrium and, after careful navigation, the clip 
Figure 1. Baseline, grade 4, mitral regurgitation in TEE
Figure 2. MitraClip (arrow) in the LV cavity before grasping 
of the mitral leaflets
Figure 3. TEE after implantation of the first MitraClip (arrow)
was introduced to the LV cavity (Fig. 2). Next, the mitral 
valve leaflets were grasped in the most medial location 
of the regurgitant jet. In the TEE, the mean pressure 
gradient (MPG) was 2.6 mm Hg and the mitral valve 
area (MVA) calculated from pressure half-time (PHT) 
was 2.7 cm2. The decision to implant another clip was 
made due to severe 4+ lateral regurgitant jet (Fig. 3). 
After the second clip implantation, just lateral to the 
first one, the MPG was 2.9 mm Hg and the MVA cal-
culated from PHT was 2.6–2.7 cm2 in the TEE. There 
was also moderate (3+) lateral regurgitant jet with 
vena contracta 6 mm in the TEE. The interventional 
team made a decision to implant next clip, lateral to the 
implanted ones. After that MPG increased to 3.5 mm 
Hg and the MVA calculated from PHT decreased to 
2.5 cm2. Unfortunately, lateral regurgitant jet persisted 
moderate (3+), with vena contracta 0.6 cm. The MR 
severity was reduced to 2+ (Fig. 4), with MPG 4.0 mm 
Hg and the MVA calculated from PHT 2.5 cm2 after 
implantation of four MC (Fig. 5). The patient was he-
modynamically stable and we finished the procedure 
without any complications. The femoral vein access 
was protected with suture and pressure dressing. 
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Figure 4. Final, grade 2, mitral regurgitation in TEE after 
implantation of four MitraClips (arrow — only one MitraClip 
visualized in this view)
Figure 5. Final fluoroscopy after implantation of four 
MitraClips (asterisks)
In the control TTE four hours after the procedure, there 
was a slight increase in MR to 2+/3+, probably due to 
different examination condition of the patient. 
Discussion 
Catheter-based repair of the mitral valve using 
MC therapy may be an alternative to surgery for 
patients with high risk of operation due to severe, 
symptomatic, functional MR, prior MI, high NYHA 
class, decreased LVEF and with a history of cardiac 
surgery. The EVEREST II study [6] (Endovascular 
Valve Edge-to-Edge Repair Study) showed that MC 
is less effective in reducing MR than conventional 
surgery, although it proved superior safety of MC 
procedure and comparable improvements of NYHA 
class and quality of life. MC therapy turned out to 
be a valuable option also for critically ill patients 
who would persistently need inotropes or who could 
not be weaned from a ventilator [7]. The described 
procedure is unique because, to the best of our 
knowledge, this is the first case in Poland that four 
clips were implanted during the treatment using 
the MC system. Reported cases of the implantation 
of four or more clips are very rare in the literature. 
In the ACCESS-EU registry [8], 3 or more devices 
were implanted in < 3% of patients. In a study by 
Koifman et al. [3] and French registry [5], none of the 
patients had more than 2 clips implanted. A registry 
from Switzerland [4] also showed that in none of the 
cases 4 clips were used and only two patients (3%) 
received 3 clips. In a study by Franzen et al. [9], 
the highest number of implanted devices was 3 in 
one patient (2%). Four clips were implanted only in 
one patient (3%) in a study by Gaemperli et al. [10].
Conclusions
The presented case report illustrates, as the first 
one in Poland, a very rare need for implantation of 
4 MC devices in a symptomatic patient with severe 
functional MR and indicates feasibility and safety of 
such management. 
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